company background image
CRDL

Cardiol Therapeutics TSX:CRDL Stock Report

Last Price

CA$1.70

Market Cap

CA$105.3m

7D

-1.7%

1Y

-43.0%

Updated

29 Jun, 2022

Data

Company Financials +
CRDL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CRDL Stock Overview

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD).

Cardiol Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cardiol Therapeutics
Historical stock prices
Current Share PriceCA$1.70
52 Week HighCA$6.19
52 Week LowCA$1.31
Beta1.06
1 Month Change-1.16%
3 Month Change-11.92%
1 Year Change-42.95%
3 Year Change-61.36%
5 Year Changen/a
Change since IPO-59.04%

Recent News & Updates

Shareholder Returns

CRDLCA PharmaceuticalsCA Market
7D-1.7%-4.3%0.3%
1Y-43.0%-72.5%-3.7%

Return vs Industry: CRDL exceeded the Canadian Pharmaceuticals industry which returned -71.4% over the past year.

Return vs Market: CRDL underperformed the Canadian Market which returned -2.9% over the past year.

Price Volatility

Is CRDL's price volatile compared to industry and market?
CRDL volatility
CRDL Average Weekly Movement15.6%
Pharmaceuticals Industry Average Movement11.9%
Market Average Movement10.0%
10% most volatile stocks in CA Market17.2%
10% least volatile stocks in CA Market4.4%

Stable Share Price: CRDL is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: CRDL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
2017n/aDavid Elsleyhttps://www.cardiolrx.com

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure.

Cardiol Therapeutics Fundamentals Summary

How do Cardiol Therapeutics's earnings and revenue compare to its market cap?
CRDL fundamental statistics
Market CapCA$105.30m
Earnings (TTM)-CA$31.68m
Revenue (TTM)CA$78.76k

1,339x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRDL income statement (TTM)
RevenueCA$78.76k
Cost of RevenueCA$0
Gross ProfitCA$78.76k
Other ExpensesCA$31.76m
Earnings-CA$31.68m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.51
Gross Margin100.00%
Net Profit Margin-40,226.63%
Debt/Equity Ratio0%

How did CRDL perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CRDL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRDL?

Other financial metrics that can be useful for relative valuation.

CRDL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue388x
Enterprise Value/EBITDA-0.8x
PEG Ration/a

Price to Book Ratio vs Peers

How does CRDL's PB Ratio compare to its peers?

CRDL PB Ratio vs Peers
The above table shows the PB ratio for CRDL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.9x
RWB Red White & Bloom Brands
0.6xn/aCA$78.8m
HUGE FSD Pharma
0.7xn/aCA$40.7m
XLY Auxly Cannabis Group
0.4x80.6%CA$62.9m
XTRX Adastra Holdings
1.8xn/aCA$39.2m
CRDL Cardiol Therapeutics
1.5x59.2%CA$105.3m

Price-To-Book vs Peers: CRDL is expensive based on its Price-To-Book Ratio (1.5x) compared to the peer average (0.9x).


Price to Earnings Ratio vs Industry

How does CRDL's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?

Price-To-Book vs Industry: CRDL is expensive based on its Price-To-Book Ratio (1.5x) compared to the Canadian Pharmaceuticals industry average (1x)


Price to Book Ratio vs Fair Ratio

What is CRDL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRDL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CRDL's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of CRDL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CRDL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CRDL's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CRDL's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Cardiol Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


59.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRDL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).

Earnings vs Market: CRDL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CRDL is expected to become profitable in the next 3 years.

Revenue vs Market: CRDL's revenue (47.4% per year) is forecast to grow faster than the Canadian market (6.6% per year).

High Growth Revenue: CRDL's revenue (47.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CRDL's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Cardiol Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-35.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CRDL is currently unprofitable.

Growing Profit Margin: CRDL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CRDL is unprofitable, and losses have increased over the past 5 years at a rate of 35.6% per year.

Accelerating Growth: Unable to compare CRDL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRDL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (118.1%).


Return on Equity

High ROE: CRDL has a negative Return on Equity (-45.77%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Cardiol Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CRDL's short term assets (CA$78.7M) exceed its short term liabilities (CA$10.2M).

Long Term Liabilities: CRDL's short term assets (CA$78.7M) exceed its long term liabilities (CA$60.7K).


Debt to Equity History and Analysis

Debt Level: CRDL is debt free.

Reducing Debt: CRDL had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CRDL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CRDL has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 34.1% each year.


Discover healthy companies

Dividend

What is Cardiol Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRDL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRDL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRDL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRDL's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CRDL has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

David Elsley

5.42yrs

Tenure

CA$1,259,787

Compensation

Mr. David G. Elsley, MBA, has been the President, Chief Executive Officer and Director of Cardiol Therapeutics Inc since January 19, 2017. Mr. Elsley is a business leader with a proven track record of deve...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD977.04K) is above average for companies of similar size in the Canadian market ($USD174.83K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CRDL's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: CRDL's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CRDL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.2%.


Top Shareholders

Company Information

Cardiol Therapeutics Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Cardiol Therapeutics Inc.
  • Ticker: CRDL
  • Exchange: TSX
  • Founded: 2017
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$105.298m
  • Shares outstanding: 61.94m
  • Website: https://www.cardiolrx.com

Number of Employees


Location

  • Cardiol Therapeutics Inc.
  • 2265 Upper Middle Road East
  • Suite 602
  • Oakville
  • Ontario
  • L6H 0G5
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.